Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Reprogramming Rx

Nature Medicine volume 17, pages 241–243 (2011)Cite this article

Subjects

Patient-specific stem cells have been heralded as the next frontier in regenerative medicine. Although most therapies are probably a decade or more away, for one life-threatening skin disease the first clinical trials involving induced pluripotent stem cells may begin as early as 2014. Monya Baker investigates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Monya Baker is technology editor for Nature and Nature Methods in San Francisco.,

    Monya Baker

Authors
  1. Monya Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baker, M. Reprogramming Rx. Nat Med 17, 241–243 (2011). https://doi.org/10.1038/nm0311-241

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0311-241

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing